SETD6: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

Target Name: SETD6

NCBI ID: G79918

SETD6

Other Name(s): N-lysine methyltransferase SETD6 (isoform a) | SETD6_HUMAN | SETD6 variant 2 | N-lysine methyltransferase SETD6 (isoform b) | N-lysine methyltransferase SETD6 | SET domain containing 6, protein lysine methyltransferase | SET domain containing 6, protein lysine methyltransferase, transcript variant 1 | SET domain-containing protein 6 | SETD6 variant 1 | SET domain containing 6, protein lysine methyltransferase, transcript variant 2

SETD6: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

N-lysine methyltransferase SETD6 (SETD6) is a enzyme that plays a crucial role in the regulation of gene expression in various organisms, including humans. SETD6 is a key enzyme in the methylation-response pathway, which involves the transfer of methyl groups from the methyl-transferase to the target gene. This pathway is involved in a wide range of physiological processes in the cell, including cell growth, apoptosis, and chromatin structure and composition.

SETD6 has been identified as a potential drug target or biomarker due to its involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The methylation-response pathway has been implicated in the development and progression of many diseases, including cancer, andSETD6 has been shown to be involved in the regulation of key genes involved in these processes.

Diseases associated with SETD6

SETD6 has been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

1. Cancer

Studies have shown thatSETD6 is involved in the regulation of key genes involved in cancer development, including the genes responsible for the development of breast cancer. For example, SETD6 has been shown to be involved in the regulation of the gene PIK3CA, which encodes a protein that is involved in cell signaling and has been shown to be involved in the development of breast cancer.

2. Neurodegenerative diseases

SETD6 has also been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown thatSETD6 is involved in the regulation of key genes involved in the development and progression of these diseases, including the genes responsible for the production of the protein tau.

3. Developmental disorders

SETD6 has also been implicated in the development and progression of developmental disorders, including Rett syndrome and Down syndrome. Studies have shown thatSETD6 is involved in the regulation of key genes involved in the development and progression of these disorders.

Mechanisms of action

SETD6 is an enzyme that is involved in the regulation of the methylation-response pathway. This pathway involves the transfer of methyl groups from the methyl-transferase to the target gene, which can modulate gene expression and contribute to the regulation of cellular processes.

SETD6 is involved in the regulation of the methylation-response pathway by participating in the transfer of methyl groups from the methyl-transferase to the target gene. This process involves the formation of a complex between SETD6 and the methyl-transferase, which is then followed by the transfer of methyl groups from the methyl-transferase to the target gene.

SETD6 has been shown to play a role in the regulation of gene expression by modulating the activity of the methyl-transferase and the target genes. This can result in the activation or repression of specific genes, which can contribute to the regulation of cellular processes.

Targeting SETD6

SETD6 is a potential drug target or biomarker due to its involvement in various diseases. The development of new treatments forSETD6-related diseases may have a significant impact on healthcare.

1. Cancer

The development of new treatments for cancer may have a significant impact on survival rates and quality of life. SETD6 has been shown to be involved in the regulation of key genes involved in cancer development, including the genes responsible for the development of breast cancer. TargetingSETD6 with new treatments may have a significant impact on the development and progression of cancer.

2. Neurodegenerative diseases

SETD6 has also been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. TargetingSETD6 with new treatments may have a significant impact on the development and progression of these diseases.

3. Developmental disorders

SETD6 has also been implicated in the development and progression of developmental disorders, including Rett syndrome and Down syndrome. TargetingSETD6 with new treatments may have a significant impact on the development and progression of these disorders.

Conclusion

SETD6 is an enzyme that plays a crucial role in the regulation of gene expression in various organisms, including humans. SETD6 is a potential drug target or biomarker due to its involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The development of new treatments forSETD6-related diseases may have a significant impact on healthcare. Further research is needed to fully understand the role ofSETD6 in the regulation of gene expression and the development and progression of various diseases.

Protein Name: SET Domain Containing 6, Protein Lysine Methyltransferase

Functions: Protein-lysine N-methyltransferase. Monomethylates 'Lys-310' of the RELA subunit of NF-kappa-B complex, leading to down-regulation of NF-kappa-B transcription factor activity (PubMed:21131967, PubMed:30189201, PubMed:21515635). Monomethylates 'Lys-8' of H2AZ (H2AZK8me1) (PubMed:23324626). Required for the maintenance of embryonic stem cell self-renewal (By similarity). Methylates PAK4

The "SETD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets